About: Renal-Cell Carcinoma

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Renal-Cell Carcinoma Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 December 2005

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в грудні 2005 (uk) im Dezember 2005 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu n'avientu de 2005 (ast) scientific article published on 01 December 2005 (en)
publication date	wds:Q56019528-D7385EA6-D94E-43E7-8649-09FA5F5D6AE9
publication date	2005-12-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q56019528-47A3F84A-3E62-4873-AB35-46753FC72D78
language of work or name	English
cites work	wds:Q56019528-24113E77-0260-4165-AA80-A6FD5FB77FE0
cites work	The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
author name string	wds:Q56019528-18CE6C53-FC01-4A87-8EE6-6F5C88ADD53C
author name string	Francis J McGovern
rdfs:label	Renal-Cell Carcinoma (en) Renal-Cell Carcinoma (nl)
skos:prefLabel	Renal-Cell Carcinoma (en) Renal-Cell Carcinoma (nl)
name	Renal-Cell Carcinoma (en) Renal-Cell Carcinoma (nl)
author	wds:Q56019528-ADF6C779-D2BE-4617-B3BC-F720309B3012
author	Herbert T Cohen
title	wds:Q56019528-EF50853E-D948-4693-A870-7724C2161108
title	Renal-cell carcinoma (en)
page(s)	wds:Q56019528-2800AC31-9986-49E0-A61B-DE2651BBE6A6
page(s)	2477-2490
instance of	wds:Q56019528-3372b992-61c6-4547-a4a8-72d5a74d134c wds:Q56019528-E07AB7A4-E49F-4C31-AD46-603886D7CE1F
instance of	review article scholarly article
PubMed ID	wds:Q56019528-075EC257-4C23-4252-9027-692EBBDAE6A4
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/16339096
PubMed ID	16339096
published in	wds:Q56019528-78D49027-5B7D-46BA-AD06-F5870B7AB315
published in	The New England Journal of Medicine
issue	wds:Q56019528-ACF28585-A89B-4ED7-8F7E-E487E4856DC2
volume	wds:Q56019528-2AD0448D-6E7A-4969-8742-2CBE7743BAFC
issue	23
volume	353
DOI	wds:Q56019528-D6125D07-DC68-48D3-8D1B-E618F2E61775
DOI	http://dx.doi.org/10.1056/NEJMRA043172
DOI	10.1056/NEJMRA043172
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q56019528
is cites work of	Regulation of receptor for activated C kinase 1 protein by the von Hippel-Lindau tumor suppressor in IGF-I-induced renal carcinoma cell invasiveness Percutaneous ablation in the kidney Aberrant epithelial morphology and persistent epidermal growth factor receptor signaling in a mouse model of renal carcinoma Application of renal-rotation techniques in retroperitoneoscopic partial nephrectomy Oncolytic targeting of renal cell carcinoma via encephalomyocarditis virus Surgical management of localised renal cell carcinoma Surgical managment of localised renal cell carcinoma Signaling pathways in renal cell carcinoma Determination of angptl4 mRNA as a diagnostic marker of primary and metastatic clear cell renal-cell carcinoma Genome-wide screening of copy number alterations and LOH events in renal cell carcinomas and integration with gene expression profile Interrogation of genomes by molecular copy-number counting (MCC). Physical activity during adulthood and adolescence in relation to renal cell cancer PD-L1 expression in nonclear-cell renal cell carcinoma Characterization of N-diethylnitrosamine-initiated and ferric nitrilotriacetate-promoted renal cell carcinoma experimental model and effect of a tamarind seed extract against acute nephrotoxicity and carcinogenesis The specificity of urinary aquaporin 1 and perilipin 2 to screen for renal cell carcinoma Primary cell cultures from human renal cortex and renal-cell carcinoma evidence a differential expression of two spliced isoforms of Annexin A3. Sunitinib combined with angiotensin-2 type-1 receptor antagonists induces more necrosis: a murine xenograft model of renal cell carcinoma Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma Multilocular cystic renal cell carcinoma is a subtype of clear cell renal cell carcinoma Delta-like ligand 4: A predictor of poor prognosis in clear cell renal cell carcinoma The angiogenic makeup of human hepatocellular carcinoma does not favor vascular endothelial growth factor/angiopoietin-driven sprouting neovascularization Immunotherapy for advanced renal cell cancer Immunotherapy for advanced renal cell cancer Quantitative assessment of solid renal masses by contrast-enhanced ultrasound with time-intensity curves: how we do it. Tensin3 is a negative regulator of cell migration and all four Tensin family members are downregulated in human kidney cancer Recent advances in the therapy of renal cancer High-dose interleukin-2 therapy for metastatic renal cell carcinoma: a contemporary experience What can molecular pathology contribute to the management of renal cell carcinoma? Vasoactive intestinal peptide induces oxidative stress and suppresses metastatic potential in human clear cell renal cell carcinoma Strong expression of chemokine receptor CXCR4 by renal cell carcinoma cells correlates with metastasis Polycystin-1 regulates the stability and ubiquitination of transcription factor Jade-1 CYLD: a deubiquitination enzyme with multiple roles in cancer. How were new medicines discovered? Integrated profiling of microRNAs and mRNAs: microRNAs located on Xq27.3 associate with clear cell renal cell carcinoma Clinical experience with everolimus in the second-line treatment of advanced renal cell carcinoma Decoy receptor 3 is a prognostic factor in renal cell cancer Targeted therapeutic strategies for the management of renal cell carcinoma Protein kinase inhibitors in renal cell carcinoma. Digitoxin as an anticancer agent with selectivity for cancer cells: possible mechanisms involved Critical role of TRPC6 channels in the development of human renal cell carcinoma Hypoxia-inducible factor linked to differential kidney cancer risk seen with type 2A and type 2B VHL mutations. Everolimus Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma Common reduction of the Raf kinase inhibitory protein in clear cell renal cell carcinoma Targeted anti-cancer therapies for renal cancer Reduced cytosolic carboxypeptidase 6 (CCP6) level leads to accumulation of serum polyglutamylated DNAJC7 protein: A potential biomarker for renal cell carcinoma early detection Immunotherapy for renal cell cancer in the era of targeted therapy Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America Validation of SELDI-TOF MS serum protein profiles for renal cell carcinoma in new populations FoxOs enforce a progression checkpoint to constrain mTORC1-activated renal tumorigenesis Sorafenib and sunitinib: novel targeted therapies for renal cell cancer [Renal cell carcinoma: Drug therapy and prognostic models] Optical property measurements establish the feasibility of photodynamic therapy as a minimally invasive intervention for tumors of the kidney Resistance to Targeted Therapies in Renal Cancer: The Importance of Changing the Mechanism of Action. Decreased Expression of SETD2 Predicts Unfavorable Prognosis in Patients With Nonmetastatic Clear-Cell Renal Cell Carcinoma EZH2 promotes tumor progression by increasing VEGF expression in clear cell renal cell carcinoma Neutrophil chemokines secreted by tumor cells mount a lung antimetastatic response during renal cell carcinoma progression

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 190 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software